Evofem Biosciences Inc. has announced notable findings from a clinical study on SOLOSEC® (secnidazole) 2 g oral granules, targeting recurrent bacterial vaginosis $(BV)$. These results were presented at the 2025 American College of Obstetricians and Gynecologists $(ACOG)$ Annual Clinical and Scientific Meeting. The study, involving 24 women, explored the efficacy of once-weekly SOLOSEC dosing. Findings indicate that the treatment effectively suppresses BV recurrence, potentially outperforming current CDC-recommended treatments. The simplicity of the once-weekly oral dose may enhance treatment adherence. While SOLOSEC is approved for BV treatment in women aged 12 and older, its use for recurrent BV is still investigational. The study's lead investigator, Dr. Chemen M. Neal, intends to submit the findings for publication in a peer-reviewed journal.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.